Combination Treatment for COPD

• Autores: Rebecca Voelker
• Localización: JAMA: the journal of the American Medical Association, ISSN 0098-7484, Vol. 315, Nº. 21, 2016, pág. 2268
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • The FDA has approved a fixed-dose dual bronchodilator that combines glycopyrrolate and formoterol fumarate in a pressurized, metered-dose inhaler. The drug, marketed as Bevespi Aerosphere, is indicated for long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD) (http://1.usa.gov/1qVyi94).

    Glycopyrrolate is a long-acting muscarinic antagonist (LAMA) while formoterol fumarate is a long-acting β2-agonist (LABA). Manufacturer AstraZeneca said in a statement that the combination medication is the first FDA-approved product using its unique technology that distributes drug crystals in a uniform suspension formed with porous, low-density phospholipid particles. The technology prevents the drug crystals from settling or intermingling, allowing consistent doses of different drugs to be dispensed from a single pressurized metered-dose inhaler (http://bit.ly/1VBpmTq).